The UNAIDS 10-point plan for making progress on prevention omits elements of the “research-to-rollout” continuum, and leaves the definition of prevention out—focusing on the “how” rather than the “what”. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
The UNAIDS 10-Point Plan for Making Progress on Prevention
US Public Sector Investment in HIV Prevention R&D, Compared to All Other Funding, 2012–2016
This graphic tracks US public sector investment in HIV prevention research & development vs all other funding sources over the four year period of 2012-2016. For much more on HIV prevention research & development funding, visit www.hivresourcetracking.org.
Driving Product Introduction and Access
AVAC has always advocated for closing critical prevention gaps. Now we’re taking our mission further. With African and global partners, we’re stepping beyond advocacy to generate the knowledge and tools that countries need to more quickly deliver new advances.
We’re engaging directly with national decision-makers to identify and overcome delivery hurdles for PrEP. We’re examining the preferences and experiences of people at high risk for HIV, so that future tools—long-acting injectables, vaginal rings and others—can be optimized to meet their needs.
AVAC Report 2017: Mixed messages and how to untangle them
AVAC is excited to share our annual “state of the field” report on biomedical prevention research and implementation. AVAC Report 2017: Mixed Messages and How to Untangle Them is straight talk about today’s complex context for HIV prevention. Read this report if you’ve wondered that there’s more rhetorical support than ever for HIV prevention but no more money? How can the world be “on the path to epidemic control” while human rights are trampled in many places, and rates of HIV diagnoses climb in others? How can scientists be so sure they know what women want, without doing research to find out?
For more from the report, including a link to all its graphics, visit avac.org/report2017.
Px Wire October-December 2017, Vol. 10, No. 4
In Px Wire, we preview part of the AVAC Report 2017, which includes a set of recommendations and priorities that keep funding and research crossing-cutting, strategic and responsive to people’s real-world needs. Check out the infographic, which provides a visual history of the DAIDS Networks and a look at what’s proposed for the next funding cycle.
An Advocate’s Guide to the DAIDS Trial Networks Funding Recompetition Process
This factsheet lays out for advocates how funding decisions under discussion at the US Division of AIDS (DAIDS) could impact communities all over the world. Read on to learn how advocates can help shape the current funding discussion and how the DAIDS process works, for future reference.
Trial Trial Again: Getting research right for adolescents
Both research and advocacy for HIV prevention are intensifying their focus on young people. Bringing interventions that work for this population holds unique challenges.
In this episode of AVAC’s Px Pulse podcast series, AVAC’s Manju Chatani-Gada explores how and why prevention research must reach the next generation.
Testing Long-Acting PrEP, Easier Said Than Done
In this episode of AVAC’s Px Pulse podcast series, leading researcher Dr. Deborah Donnell tells us why the HIV Prevention Trials Network (HPTN) changed the design of one of two trials testing long-acting cabotegravir, as an injectable PrEP.
PrEP and Trial Design — A no brainer for some
In this episode of AVAC’s Px Pulse podcast series, Slim Abdool Karim, co-principal investigator of the landmark CAPRISA 004 study, talks about why designing trials with oral PrEP is a must—scientifically and ethically.
Golden Age or Fools Gold?
In this episode of AVAC’s Px Pulse podcast series, Carl Dieffenbach, Director of NIH’s Division of AIDS, tells AVAC where he sees the most promise in the field of HIV prevention and what it will take to “put out the fire.”